Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000256962 | SCV000324683 | pathogenic | Breast-ovarian cancer, familial, susceptibility to, 2 | 2016-10-18 | reviewed by expert panel | curation | Variant allele predicted to encode a truncated non-functional protein. |
Labcorp Genetics |
RCV000496717 | SCV001582818 | pathogenic | Hereditary breast ovarian cancer syndrome | 2023-12-31 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys2860Argfs*3) in the BRCA2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA2 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast cancer (PMID: 20927582, 29681614). This variant is also known as 8804delA. ClinVar contains an entry for this variant (Variation ID: 52627). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005007979 | SCV005633985 | pathogenic | Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 2; Fanconi anemia complementation group D1; Medulloblastoma; Wilms tumor 1; Pancreatic cancer, susceptibility to, 2; Glioma susceptibility 3; Familial prostate cancer | 2024-04-29 | criteria provided, single submitter | clinical testing | |
Research Molecular Genetics Laboratory, |
RCV000496717 | SCV000587963 | pathogenic | Hereditary breast ovarian cancer syndrome | 2014-01-31 | no assertion criteria provided | research |